"Affimed’s stock is a rollercoaster—delisting fears vs. promising cancer data! 📉🚀 The 9-day WMA just spiked past the 21-day, hinting at a potential rebound, but RSI is still in the 'oversold basement' (33). Wild volume screams 'someone knows something'—maybe that AACR update is a sleeper hit? Chart’s a mess, but if you’re gutsy, this could be a speculative BUY before the next catalyst. High risk, high reward. #BiotechBets"